Evaluating the clinical significance of diazepam binding inhibitor in alzheimer's disease: A comparison with inflammatory, oxidative, and neurodegenerative biomarkers

Basit Öğe Kaydı
dc.authorid0000-0002-2306-5937
dc.contributor.authorGökçe, Mustafa
dc.contributor.authorVelioğlu, Halil Aziz
dc.contributor.authorBektay, Muhammed Yunus
dc.contributor.authorGüler, Eray Metin
dc.date.accessioned2023-10-26T06:59:06Z
dc.date.available2023-10-26T06:59:06Z
dc.date.issued2023
dc.departmentİstanbul Medipol Üniversitesi, Rektörlük, Rejeneratif ve Restoratif Tıp Araştırmaları Merkezi (REMER)
dc.departmentİstanbul Medipol Üniversitesi, Rektörlük, Sağlık Bilim ve Teknolojileri Araştırma Enstitüsü
dc.description.abstractIntroduction: Alzheimer's disease (AD) is one of the pathologies that the scientific world is still desperate for. The aim of this study was the investigation of diazepam binding inhibitor (DBI) as a prognostic factor for AD prognosis. Methods: A total of 120 participants were divided into 3 groups. Forty new diagnosed Alzheimer patients (NDG) who have been diagnosed but have not started AD treatment, 40 patients who diagnosed 5 years ago (D5YG), and 40 healthy control groups (CG) were included in the study. Levels of DBI, oxidative stress, inflammatory, and neurodegenerative biomarkers were compared between 3 groups. Results: Plasma levels of DBI, oligomeric A?, total tau, glial fibrillary acidic protein, ?-synuclein, interleukin (IL) 1?, IL6, tumor necrosis factor ?, oxidative stress index, high-sensitive C-reactive protein, and DNA damage were found higher in D5YG and NDG as compared to CG (p < 0.001). On the contrary, plasma levels of total thiol, native thiol, vitamin D and vitamin B12 were lower in D5YG and NDG as compared to CG (p < 0.001). Discussion: DBI may be a potential plasma biomarker and promising drug target for AD. It could help physicians make a comprehensive evaluation with cognitive and neurodegenerative tests.
dc.identifier.citationGökçe, M., Velioğlu, H. A., Bektay, M. Y. ve Güler, E. M. (2023). Evaluating the clinical significance of diazepam binding inhibitor in alzheimer's disease: A comparison with inflammatory, oxidative, and neurodegenerative biomarkers. Gerontology, 69(9), 1104-1112. https://dx.doi.org/10.1159/000531849
dc.identifier.doi10.1159/000531849
dc.identifier.endpage1112
dc.identifier.issn0304-324X
dc.identifier.issn1423-0003
dc.identifier.issue9
dc.identifier.pmid37607528
dc.identifier.scopus2-s2.0-85170555128
dc.identifier.scopusqualityQ1
dc.identifier.startpage1104
dc.identifier.urihttps://dx.doi.org/10.1159/000531849
dc.identifier.urihttps://hdl.handle.net/20.500.12511/11643
dc.identifier.volume69
dc.identifier.wos001067761300006en_US
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorVelioğlu, Halil Aziz
dc.language.isoen
dc.publisherKarger
dc.relation.ispartofGerontologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsAttribution-NonCommercial 4.0 International*
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/deed.en*
dc.subjectDiazepam Binding Inhibitor
dc.subjectAlzheimer’s Disease
dc.subjectAgeing
dc.subjectBiomarker
dc.subjectInflammation
dc.subjectOxidative Stress
dc.titleEvaluating the clinical significance of diazepam binding inhibitor in alzheimer's disease: A comparison with inflammatory, oxidative, and neurodegenerative biomarkers
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Velioglu-Halil-2023.pdf
Boyut:
492.32 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu